NBD AI Bulletin - Guangzhou Kingmed Diagnostics Group Co Ltd ("the Company", SH 603882, closing price: 86.2 yuan) announced on the evening of November 13 that it has received a notice from shareholder Guochuang Kaiyuan Equity Investment Fund (Limited Partnership) concerning the progress of the share selldown plan. To date, the shareholder's selldown has been completed, with around 5.58 million shares, or 1.21% of the Company's total shares, having been sold at a price of between 70.16 yuan/share and 106.40 yuan/share.
The 2019 annual report shows that Guangzhou Kingmed Diagnostics Group Co Ltd mainly engages in third-party medical diagnosis, accounting for 94.22% of its revenue.
Guangzhou Kingmed Diagnostics Group Co Ltd's general manager and chairman is Liang Yaoming, male, 56 years old, Chinese national, no overseas permanent residency, MBA.
Tips on "Stock Trends":
1. The number of shares held by northbound investors in the Company increased by 3.0845 million in the past 30 days, representing 0.64% of the Company's circulating shares;
2. There was no institutional research on the Company in the past 30 days;
3. Guangzhou Kingmed Diagnostics Group Co Ltd last issued a share selldown announcement on November 12, 2020, with shares down 0.75% the next trading day. In the past 12 months, the Company released a total of 18 announcements of such kind.
(By Lan Suying)
Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.